Quatresooz P, Piérard G E
Department of Dermatopathology, University Hospital Sart Tilman, Liège, Belgium.
Clin Exp Dermatol. 2003 Nov;28 Suppl 1:27-9. doi: 10.1046/j.1365-2230.28.s1.9.x.
Dermal dendrocytes (DDs) are dendritic cells that exhibit immunoreactivity for factor XIIIa, and are frequently found in conjunction with basal cell carcinomas (BCCs). Imiquimod was applied to 12 superficial BCCs every 3 days for 8 weeks. One week after completion of treatment, seven lesions appeared to have resolved, while five displayed evidence of residual BCC. Prior to initiation of treatment, the seven imiquimod-responsive BCCs were surrounded by numerous DDs, whereas the five imiquimod-resistant BCCs had fewer DDs next to them at the time of entry into the study. It appears that the pretreatment density in DDs may affect the efficacy of imiquimod in eradicating skin tumours.
真皮树突状细胞（DDs）是对因子ⅩⅢa具有免疫反应性的树突状细胞，且经常与基底细胞癌（BCCs）同时出现。咪喹莫特每3天应用于12例浅表性基底细胞癌，持续8周。治疗结束1周后，7个病灶似乎已消退，而5个病灶显示有残留基底细胞癌的迹象。在开始治疗前，7个对咪喹莫特敏感的基底细胞癌周围有大量真皮树突状细胞，而在进入研究时，5个对咪喹莫特耐药的基底细胞癌旁边的真皮树突状细胞较少。看来真皮树突状细胞的预处理密度可能会影响咪喹莫特根除皮肤肿瘤的疗效。
